• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Normalol
    / Dexcel


    Active Ingredient
    Atenolol 25, 50, 100 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    30 x 25 mg

    full basket chart 9546 14081

    Tablets

    30 x 50 mg

    full basket chart 8315 14359

    Tablets

    30 x 100 mg

    full basket chart 8314 14360

    Related information


    Dosage

    The dose must always be adjusted to individual requirements of the patients, with the lowest possible starting dosage.
    Angina pectoris:
    Initial: 50mg daily, the dosage being increased gradually to 100 mg after 1 week, as needed and tolerated.
    Late Intervention after Acute Myocardial Infarction: 100 mg daily.
    Hypertension: Initially 25-50 mg daily, the dosage being increased gradually after two weeks to 100 mg a daily, as needed and tolerated.
    Elderly: Dosage requirements may be reduced, especially in patients with impaired renal function.
    Children: not recommended for use in children.
    Renal failure: the dosage should be adjusted in cases of severe impairment of renal function.
    No significant accumulation of Atenolol occurs in patients who have a creatinine clearance greater than 35 ml/min/1.73 m2 (normal range is 100–150 ml/min/1.73 m2). For patients with a creatinine clearance of 15–35 ml/min/1.73 m2 (equivalent to serum creatinine of 300–600 micromol/litre), the oral dose should be 50 mg daily. For patients with a creatinine clearance of less than 15 ml/min/1.73 m2 (equivalent to serum creatinine of greater than 600 micromol/litre), the oral dose should be 25 mg daily or 50 mg on alternate days. Patients on haemodialysis should be given 50 mg orally after each dialysis; This should be done under hospital supervision as marked falls in blood pressure can occur.


    Indications

    Treatment of angina pectoris, acute myocardial infarction, hypertension.


    Contra-Indications

    Concomitant use with other beta blockers. Pediatric patients. Patients with: Hypersensitivity to the active substance, or to any of the excipients. Cardiogenic shock. Uncontrolled Heart failure. Sick sinus syndrome. 2nd or 3rd degree heart block. Untreated phaeochromocytoma. Metabolic acidosis. Bradycardia (<45 bpm). Hypotension. Severe peripheral arterial circulatory disturbances.


    Special Precautions

    For additional information, please contact the license holder.


    Side Effects

    For additional information, please contact the license holder.


    Drug interactions

    For additional information, please contact the license holder.


    Pregnancy and Lactation

    For additional information, please contact the license holder.


    Overdose

    For additional information, please contact the license holder.


    Manufacturer
    Dexcel Ltd.
    Licence holder
    CLOSE